Evidence map›Paper›PMID 42243536›Full record

ArticleNature chemical biology2026

The antiphage mechanism of a widespread trypsin-MBL defense module.

Pingping Huang, Jingxian Liu, Lijie Guo, Dongyang Xu, Lingbo Shen, Purui Yan, Chen Tong, Wenying Fei, Mengjun Cheng, Zhaoxing Li and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pingping Huang *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Jingxian Liu *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Lijie Guo *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Dongyang Xu *Institute of Genomics, School of Medicine, Huaqiao University, Xiamen, China.ORCID http://orcid.org/0000-0002-7814-0666
Lingbo Shen *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Purui YanState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Chen TongState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Wenying FeiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Mengjun ChengShanghai Institute of Phage, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Zhaoxing LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Meiling LuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Lei ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Nannan WuFudan University Phage Institute, Zhongshan Hospital Fudan University, Shanghai, China. nannan.wu@cphage.com.ORCID http://orcid.org/0000-0003-1244-0030
Lian-Wen QiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Qilw@cpu.edu.cn.ORCID http://orcid.org/0000-0003-0728-4475
Yibei XiaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. yibei.xiao@cpu.edu.cn.ORCID http://orcid.org/0000-0003-4716-5526
Meirong ChenState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. chenmr@cpu.edu.cn.ORCID http://orcid.org/0000-0003-4315-0204

Funding

Basic Research Program of Jiangsu Province BK20250200National Natural Science Foundation of China (National Science Foundation of China) 32000441National Natural Science Foundation of China (National Science Foundation of China) 32271330National Natural Science Foundation of China (National Science Foundation of China) 32470145National Natural Science Foundation of China (National Science Foundation of China) 32471316National Natural Science Foundation of China (National Science Foundation of China) 82304614National Natural Science Foundation of China (National Science Foundation of China) 82321005National Natural Science Foundation of China (National Science Foundation of China) 82473977
6 · The paper itself

Abstract

Protease-mediated activation of immune effectors is an evolutionarily conserved mechanism. This study identifies a widespread trypsin-MBL (metallo-β-lactamase) module as a core effector in diverse antiviral bacterial immune systems, such as Hachiman, AVAST and Argonaute. Focusing on the Hachiman-associated trypsin-MBL system, we show that trypsin•HamAB protease activity is inhibited by ATP, while MBL is an autoinhibited DNase with two insertion loops obstructing its catalytic site. Upon infection, trypsin•HamAB senses foreign DNA and hydrolyzes ATP, activating trypsin-like activity, which specifically cleaves MBL at the insertion loops to release repression. The activated MBL depletes DNA and arrests host cell growth. Cryo-electron microscopy structures of trypsin•HamAB-DNA reveal that DNA binding and ATP hydrolysis trigger HamAB oligomerization and trypsin-like domain release, enabling its activation. Our work elucidates a conserved immune mechanism wherein proteolytic activation of a nuclease enables robust immunity against phage while multilayered controls prevent self-toxicity, expanding the repertoire of immune processes governed by regulatory proteolysis.

Identifiers

PMID42243536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.